Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 10, 2006, Pages 1581-1585

  Furuta, Kenji ^a   Adachi, Kyoichi ^a   Komazawa, Yoshinori ^a   Mihara, Takafumi ^a   Miki, Masaharu ^a   Azumi, Takane ^a   Fujisawa, Tomoo ^a   Katsube, Tomoko ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Famotidine; Gastroesophageal reflux; Gastroesophageal reflux disease; Helicobacter pylori; pH monitoring

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

EID: 33747586732     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04323.x     Document Type: Article

References (26)

1. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Aliment. Pharmacol. Ther. 1999; 13: 1611-20.
2. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment. Pharmacol. Ther. 1994; 8: 193-201.
3. Wilder-Smith C, Halter F, Ernst T et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment. Pharmacol. Ther. 1990; 4 (Suppl. 1): 15-27.
4. Smith JT, Gavey C, Nwokolo CU, Pounder RE. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment. Pharmacol. Ther. 1990; 4 (Suppl. 1): 47-63.
5. Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment. Pharmacol. Ther. 1990; 4 (Suppl. 1): 29-45.
6. Netzer P, Gaia C, Sandoz M et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am. J. Gastroenterol. 1999; 94: 351-7.
7. Sandvik AK, Brenna E, Waldum HL. The pharmacological inhibition of gastric acid secretion: tolerance and rebound (Review). Aliment. Pharmacol. Ther. 1997; 11: 1013-18.
8. Komazawa Y, Adachi K, Mihara T et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2003; 18: 678-82.
9. Fujisawa T, Adachi K, Komazawa Y et al. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. Aliment. Pharmacol. Ther. 2004; 20: 559-65.
10. Carlsson R, Dent J, Bolling-Sternevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastroenterol. 1998; 33: 1023-9.
11. Katsube T, Adachi K, Kawamura A et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment. Pharmacol. Ther. 2000; 14: 1049-56.
12. Adachi K, Katsube T, Kawamura A et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther. 2000; 14: 1259-66.
13. Adachi K, Ishihara S, Hashimoto T et al. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther. 2000; 14: 919-22.
14. Adachi K, Ishihara S, Hashimoto T et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther. 2001; 15: 1187-91.
15. Adachi K, Fujishiro H, Mihara T, Komazawa Y, Kinoshita Y. Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2003; 18: 168-71.
16. Adachi K, Fujishiro H, Katsube T et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J. Gastroenterol. Hepatol. 2001; 16: 1191-6.
17. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997; 41: 452-8.
18. Koike T, Ohara S, Sekine H et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4.
19. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology (Review). Gastroenterology 1997; 113 (Suppl. 6): S43-9.
20. van Herwaarden MA, Samsom M, Smout AJ. Helicobacter pylori eradication increases nocturnal acid breakthrough. Aliment. Pharmacol. Ther. 2000; 14: 961-2.
21. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16.
22. Berlin RG, Root JK, Cook TJ. Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. Aliment. Pharmacol. Ther. 1991; 5: 161-71.
23. Bianchi Porro G, Lazzaroni M, Barbara L et al. A controlled study of 20 mg famotidine nocte versus 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. Aliment. Pharmacol. Ther. 1991; 5: 181-9.
24. Festen HP. Prevention of duodenal ulcer relapse by long-term treatment with omeprazole. Scand. J. Gastroenterol. 1994; 201 (Suppl.): 39-41.
25. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J. Gastroenterol. 1999; 34: 553-9.
26. Fujishiro H, Adachi K, Kawamura A et al. Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients. J. Gastroenterol. Hepatol. 2001; 16: 1217-21.